Skip to main content
Top
Published in: Clinical and Translational Oncology 8/2020

01-08-2020 | Prostate Cancer | Research Article

Whole-body MRI: a powerful alternative to bone scan for bone marrow staging without radiation and gadolinium enhancer

Authors: I. Papageorgiou, J. Dvorak, I. Cosma, A. Pfeil, U. Teichgraeber, A. Malich

Published in: Clinical and Translational Oncology | Issue 8/2020

Login to get access

Abstract

Purpose

Whole-body magnetic resonance imaging (WB-MRI) is a radiation-free alternative to the 99mTc-HDP bone scan (BS) for the detection of bone metastasis. The major drawback is the long examination time and application of gadolinium enhancer. The aim of this study is to analyze (i) the performance of WB-MRI versus the BS and (ii) the diagnostic benefit of gadolinium (WB-MRI + Gd) compared to a non-enhanced protocol (NE WB-MRI).

Methods and materials

1256 eligible WB-MRI scans were analyzed retrospectively with a single inclusion criterion, a clinical 12-month follow-up or a biopsy as ground truth. N = 285 patients received both a WB-MRI and a BS within 12 months. All the patients were imaged with a coronal T1w and a STIR, and n = 528 (42%) received an additional T1w-mDixon with gadoteridol (0.1 mmol Gd-DTPA/kg).

Results

From 1256 eligible patients, n = 884 (70%) had breast cancer as a primary disease, n = 101(8%) prostate cancer, and n = 77(6%) lung cancer. The sensitivity (Se) and negative predictive value (NPV) of the WB-MRI was 98/99%, significantly higher compared to BS with 82/89%, P < 0.001 Mc Nemar’s test. The specificity (Spe) and positive predictive value (PPV) of the WB-MRI and BS was 85/82% and 91/86%, respectively. The interobserver agreement between WB-MRI and BS was 71%, Cohen’s kappa 0.42. Analysis of the added diagnostic value of gadolinium revealed Se/Spe/PPV/NPV of 98/93/92/98% for the NE WB-MRI and 99/93/85/100% for the WM-MRI + Gd, P > 0.05 binary logistic regression with Fischer’s exact test.

Conclusion

WB-MRI exceeds the sensitivity of BS without compromising the specificity, even after omitting the gadolinium enhancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wu L-M, Gu H-Y, Zheng J, Xu X, Lin L-H, Deng X, et al. Diagnostic value of whole-body magnetic resonance imaging for bone metastases: a systematic review and meta-analysis. J Magn Reson Imaging. 2011;34:128–35.CrossRef Wu L-M, Gu H-Y, Zheng J, Xu X, Lin L-H, Deng X, et al. Diagnostic value of whole-body magnetic resonance imaging for bone metastases: a systematic review and meta-analysis. J Magn Reson Imaging. 2011;34:128–35.CrossRef
2.
go back to reference Costelloe CM, Madewell JE, Kundra V, Harrell RK, Bassett RL, Ma J. Conspicuity of bone metastases on fast Dixon-based multisequence whole-body MRI: clinical utility per sequence. Magn Reson Imaging. 2013;31:669–75.CrossRef Costelloe CM, Madewell JE, Kundra V, Harrell RK, Bassett RL, Ma J. Conspicuity of bone metastases on fast Dixon-based multisequence whole-body MRI: clinical utility per sequence. Magn Reson Imaging. 2013;31:669–75.CrossRef
3.
go back to reference Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)†. Ann Oncol Off J Eur Soc Med Oncol. 2018;29:1634–57.CrossRef Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)†. Ann Oncol Off J Eur Soc Med Oncol. 2018;29:1634–57.CrossRef
4.
go back to reference Parker C, Gillessen S, Heidenreich A, Horwich A. ESMO Guidelines Committee Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2015;26(Suppl 5): v69–v77.CrossRef Parker C, Gillessen S, Heidenreich A, Horwich A. ESMO Guidelines Committee Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2015;26(Suppl 5): v69–v77.CrossRef
5.
go back to reference Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2018;29:iv192–iv237.CrossRef Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2018;29:iv192–iv237.CrossRef
6.
go back to reference Kosmin M, Makris A, Joshi PV, Ah-See M-L, Woolf D, Padhani AR. The addition of whole-body magnetic resonance imaging to body computerised tomography alters treatment decisions in patients with metastatic breast cancer. Eur J Cancer Oxf Engl. 1990;2017(77):109–16. Kosmin M, Makris A, Joshi PV, Ah-See M-L, Woolf D, Padhani AR. The addition of whole-body magnetic resonance imaging to body computerised tomography alters treatment decisions in patients with metastatic breast cancer. Eur J Cancer Oxf Engl. 1990;2017(77):109–16.
7.
go back to reference Di Gioia D, Stieber P, Schmidt GP, Nagel D, Heinemann V, Baur-Melnyk A. Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase. Br J Cancer. 2015;112:809–18.CrossRef Di Gioia D, Stieber P, Schmidt GP, Nagel D, Heinemann V, Baur-Melnyk A. Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase. Br J Cancer. 2015;112:809–18.CrossRef
8.
go back to reference Lecouvet FE, Talbot JN, Messiou C, Bourguet P, Liu Y, de Souza NM. Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: A review and position statement by the European Organisation for Research and Treatment of Cancer imaging group. Eur J Cancer. 2014;50:2519–31.CrossRef Lecouvet FE, Talbot JN, Messiou C, Bourguet P, Liu Y, de Souza NM. Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: A review and position statement by the European Organisation for Research and Treatment of Cancer imaging group. Eur J Cancer. 2014;50:2519–31.CrossRef
9.
go back to reference Larbi A, Dallaudière B, Pasoglou V, Padhani A, Michoux N, Vande Berg BC, et al. Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease. Prostate. 2016;76:1024–33.CrossRef Larbi A, Dallaudière B, Pasoglou V, Padhani A, Michoux N, Vande Berg BC, et al. Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease. Prostate. 2016;76:1024–33.CrossRef
10.
go back to reference Goldvaser H, Ribnikar D, Fazelzad R, Seruga B, Templeton AJ, Ocana A, et al. Influence of non-measurable disease on progression-free survival in patients with metastatic breast cancer. Cancer Treat Rev. 2017;59:46–53.CrossRef Goldvaser H, Ribnikar D, Fazelzad R, Seruga B, Templeton AJ, Ocana A, et al. Influence of non-measurable disease on progression-free survival in patients with metastatic breast cancer. Cancer Treat Rev. 2017;59:46–53.CrossRef
11.
go back to reference Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, et al. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open. 2016;6:e012799.CrossRef Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, et al. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open. 2016;6:e012799.CrossRef
12.
go back to reference Cook C, Cleland J, Huijbregts P. Creation and critique of studies of diagnostic accuracy: use of the STARD and QUADAS methodological quality assessment tools. J Man Manip Ther. 2007;15:93–102.CrossRef Cook C, Cleland J, Huijbregts P. Creation and critique of studies of diagnostic accuracy: use of the STARD and QUADAS methodological quality assessment tools. J Man Manip Ther. 2007;15:93–102.CrossRef
13.
go back to reference Lenkinski RE. Gadolinium retention and deposition revisited: how the chemical properties of gadolinium-based contrast agents and the use of animal models inform us about the behavior of these agents in the human brain. Radiology. 2017;285:721–4.CrossRef Lenkinski RE. Gadolinium retention and deposition revisited: how the chemical properties of gadolinium-based contrast agents and the use of animal models inform us about the behavior of these agents in the human brain. Radiology. 2017;285:721–4.CrossRef
14.
go back to reference Kanda T, Nakai Y, Hagiwara A, Oba H, Toyoda K, Furui S. Distribution and chemical forms of gadolinium in the brain: a review. Br J Radiol. 2017;90:20170115.CrossRef Kanda T, Nakai Y, Hagiwara A, Oba H, Toyoda K, Furui S. Distribution and chemical forms of gadolinium in the brain: a review. Br J Radiol. 2017;90:20170115.CrossRef
15.
go back to reference Gulani V, Calamante F, Shellock FG, Kanal E, Reeder SB. International Society for Magnetic Resonance in Medicine Gadolinium deposition in the brain: summary of evidence and recommendations. Lancet Neurol. 2017;16:564–70.CrossRef Gulani V, Calamante F, Shellock FG, Kanal E, Reeder SB. International Society for Magnetic Resonance in Medicine Gadolinium deposition in the brain: summary of evidence and recommendations. Lancet Neurol. 2017;16:564–70.CrossRef
16.
go back to reference O’Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: An update. World J Radiol. 2015;7:202–11.CrossRef O’Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: An update. World J Radiol. 2015;7:202–11.CrossRef
17.
go back to reference Suva LJ, Griffin RJ, Makhoul I. Mechanisms of bone metastases of breast cancer. Endocr Relat Cancer. 2009;16:703–13.CrossRef Suva LJ, Griffin RJ, Makhoul I. Mechanisms of bone metastases of breast cancer. Endocr Relat Cancer. 2009;16:703–13.CrossRef
18.
go back to reference Barchetti F, Stagnitti A, Megna V, Al Ansari N, Marini A, Musio D, et al. Unenhanced whole-body MRI versus PET-CT for the detection of prostate cancer metastases after primary treatment. Eur Rev Med Pharmacol Sci. 2016;20:3770–6.PubMed Barchetti F, Stagnitti A, Megna V, Al Ansari N, Marini A, Musio D, et al. Unenhanced whole-body MRI versus PET-CT for the detection of prostate cancer metastases after primary treatment. Eur Rev Med Pharmacol Sci. 2016;20:3770–6.PubMed
19.
go back to reference Nakanishi K, Kobayashi M, Takahashi S, Nakata S, Kyakuno M, Nakaguchi K, et al. Whole body MRI for detecting metastatic bone tumor: comparison with bone scintigrams. Magn Reson Med Sci MRMS Off J Jpn Soc Magn Reson Med. 2005;4:11–7. Nakanishi K, Kobayashi M, Takahashi S, Nakata S, Kyakuno M, Nakaguchi K, et al. Whole body MRI for detecting metastatic bone tumor: comparison with bone scintigrams. Magn Reson Med Sci MRMS Off J Jpn Soc Magn Reson Med. 2005;4:11–7.
20.
go back to reference Yang H-L, Liu T, Wang X-M, Xu Y, Deng S-M. Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT. MRI and bone scintigraphy. Eur Radiol. 2011;21:2604–17.CrossRef Yang H-L, Liu T, Wang X-M, Xu Y, Deng S-M. Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT. MRI and bone scintigraphy. Eur Radiol. 2011;21:2604–17.CrossRef
21.
go back to reference Liu T, Wang S, Liu H, Meng B, Zhou F, He F, et al. Detection of vertebral metastases: a meta-analysis comparing MRI, CT, PET, BS and BS with SPECT. J Cancer Res Clin Oncol. 2017;143:457–65.CrossRef Liu T, Wang S, Liu H, Meng B, Zhou F, He F, et al. Detection of vertebral metastases: a meta-analysis comparing MRI, CT, PET, BS and BS with SPECT. J Cancer Res Clin Oncol. 2017;143:457–65.CrossRef
22.
go back to reference Yilmaz MH, Ozguroglu M, Mert D, Turna H, Demir G, Adaletli I, et al. Diagnostic value of magnetic resonance imaging and scintigraphy in patients with metastatic breast cancer of the axial skeleton: a comparative study. Med Oncol Northwood Lond Engl. 2008;25:257–63.CrossRef Yilmaz MH, Ozguroglu M, Mert D, Turna H, Demir G, Adaletli I, et al. Diagnostic value of magnetic resonance imaging and scintigraphy in patients with metastatic breast cancer of the axial skeleton: a comparative study. Med Oncol Northwood Lond Engl. 2008;25:257–63.CrossRef
23.
go back to reference Liu T, Cheng T, Xu W, Yan W-L, Liu J, Yang H-L. A meta-analysis of 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with breast cancer. Skeletal Radiol. 2011;40:523–31.CrossRef Liu T, Cheng T, Xu W, Yan W-L, Liu J, Yang H-L. A meta-analysis of 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with breast cancer. Skeletal Radiol. 2011;40:523–31.CrossRef
24.
go back to reference Shen G, Deng H, Hu S, Jia Z. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol. 2014;43:1503–13.CrossRef Shen G, Deng H, Hu S, Jia Z. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol. 2014;43:1503–13.CrossRef
25.
go back to reference Jambor I, Kuisma A, Ramadan S, Huovinen R, Sandell M, Kajander S, et al. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 15T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Acta Oncol Stockh Swed. 2016;55:59–67.CrossRef Jambor I, Kuisma A, Ramadan S, Huovinen R, Sandell M, Kajander S, et al. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 15T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial. Acta Oncol Stockh Swed. 2016;55:59–67.CrossRef
26.
go back to reference Qu X, Huang X, Yan W, Wu L, Dai K. A meta-analysis of 18FDG-PET-CT, 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur J Radiol. 2012;81:1007–155.CrossRef Qu X, Huang X, Yan W, Wu L, Dai K. A meta-analysis of 18FDG-PET-CT, 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur J Radiol. 2012;81:1007–155.CrossRef
27.
go back to reference Liu T, Xu J-Y, Xu W, Bai Y-R, Yan W-L, Yang H-L. Fluorine-18 deoxyglucose positron emission tomography, magnetic resonance imaging and bone scintigraphy for the diagnosis of bone metastases in patients with lung cancer: which one is the best?—A meta-analysis. Clin Oncol R Coll Radiol G B. 2011;23:350–8.CrossRef Liu T, Xu J-Y, Xu W, Bai Y-R, Yan W-L, Yang H-L. Fluorine-18 deoxyglucose positron emission tomography, magnetic resonance imaging and bone scintigraphy for the diagnosis of bone metastases in patients with lung cancer: which one is the best?—A meta-analysis. Clin Oncol R Coll Radiol G B. 2011;23:350–8.CrossRef
28.
go back to reference Layne KA, Dargan PI, Archer JRH, Wood DM. Gadolinium deposition and the potential for toxicological sequelae—a literature review of issues surrounding gadolinium-based contrast agents. Br J Clin Pharmacol. 2018;84:2522–34.CrossRef Layne KA, Dargan PI, Archer JRH, Wood DM. Gadolinium deposition and the potential for toxicological sequelae—a literature review of issues surrounding gadolinium-based contrast agents. Br J Clin Pharmacol. 2018;84:2522–34.CrossRef
29.
go back to reference Elbeshlawi I, AbdelBaki MS. Safety of gadolinium administration in children. Pediatr Neurol. 2018;86:27–322.CrossRef Elbeshlawi I, AbdelBaki MS. Safety of gadolinium administration in children. Pediatr Neurol. 2018;86:27–322.CrossRef
30.
go back to reference Walker R, Kessar P, Blanchard R, Dimasi M, Harper K, DeCarvalho V, et al. Turbo STIR magnetic resonance imaging as a whole-body screening tool for metastases in patients with breast carcinoma: preliminary clinical experience. J Magn Reson Imaging. 2000;11:343–50.CrossRef Walker R, Kessar P, Blanchard R, Dimasi M, Harper K, DeCarvalho V, et al. Turbo STIR magnetic resonance imaging as a whole-body screening tool for metastases in patients with breast carcinoma: preliminary clinical experience. J Magn Reson Imaging. 2000;11:343–50.CrossRef
Metadata
Title
Whole-body MRI: a powerful alternative to bone scan for bone marrow staging without radiation and gadolinium enhancer
Authors
I. Papageorgiou
J. Dvorak
I. Cosma
A. Pfeil
U. Teichgraeber
A. Malich
Publication date
01-08-2020
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 8/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02257-x

Other articles of this Issue 8/2020

Clinical and Translational Oncology 8/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine